Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 516 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pharmacokinetic Study in Healthy Participants Clear all

Conditions: Healthy Volunteers
Interventions: LY2886721, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteer
Interventions: plerixafor, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: the Pharmacokinetic Profile of Icariin in Humans
Interventions: Icariin, Matching placebo; Drug · Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Adult Male and Female Volunteers
Interventions: ORX489 Tablets, Placebo Tablets; Drug · Other
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Major Depressive Disorder
Interventions: LY2216684, Fluoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Subjects
Interventions: Insulex® R (soluble human insulin, biosimilar), Humulin® R (soluble human insulin, biosimilar); Drug
Lead sponsor: Laboratorios Pisa S.A. de C.V.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: MGTA-145, plerixafor, Placebo; Biological
Lead sponsor: Ensoma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: Povorcitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Lansoprazole, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: Placebo, RO5508887; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: S-equol, Placebo; Drug
Lead sponsor: Ausio Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy Participants
Interventions: LY3050258, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Dabigatran etexilate mesylate, Odalasvir (ODV), Simeprevir (SMV); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Atherosclerosis
Interventions: Darapladib 160 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Healthy Volunteers
Interventions: Viagra 50 mg tablet, Formulation B ODT tablet 50 mg, Formulation C ODT tablet 50 mg, Formulation D ODT tablet 50 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: AG-348, Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: sotagliflozin (SAR439954), midazolam, metoprolol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Moderate Hepatic Impairment, Severe Hepatic Impairment, Liver Diseases
Interventions: Nitazoxanide; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami Lakes, Florida • Orlando, Florida

Conditions: Healthy Volunteer
Interventions: Pirfenidone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Merritt Island, Florida

Conditions: Healthy Subjects
Interventions: BGB-3111 and Drug Cocktail; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Hepatic Impairment
Interventions: Nalbuphine ER; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Dose Finding Study
Interventions: TAK-058 (ENV8058), Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Participants
Interventions: AG-881, Lamotrigine; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Study of LY2886721 in Healthy Participants

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

Icariin to Prevent Corticosteroid-related Memory Changes

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

A Study of LY3050258 in Healthy Participants

A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet

A Phase I Study of AG-348 in Healthy Volunteers

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants

A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects

Study of Nalbuphine ER in Participants With Hepatic Impairment

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults